Asia Pacific
Refine Search
Biotechnology
Chinese biopharma CStone Pharmaceuticals has announced a strategic commercial collaboration with Pharmalink Store, a prominent pharmaceutical company based in the United Arab Emirates (UAE). 22 November 2024
Biotechnology
Zhongshan-based biopharma company Akeso will await the verdict of the Chinese medicines regulator on a penpulimab-based combo therapy. 22 November 2024
Pharmaceutical
Shanghai-based Zai Lab and New York’s Pfizer are to work together on the commercialization of Xacduro (sulbactam-durlobactam) in China. 22 November 2024
Biotechnology
Hong Kong-based Sino Biopharm has signed an equity investment and strategic collaboration agreement with LaNova Medicines, advancing its oncology focus. 22 November 2024
Pharmaceutical
Japanese drugmaker Eisai has announced that the amyotrophic lateral sclerosis (ALS) treatment Rozebalamin for Injection (mecobalamin) has been launched in Japan as a treatment for slowing progression of functional impairment in amyotrophic lateral sclerosis. 21 November 2024
Biotechnology
San Diego-based Kura Oncology and Japan’s Kyowa Kirin have entered into a global strategic collaboration to develop and commercialize ziftomenib. 21 November 2024
Pharmaceutical
Shanghai-based Leading Tac Pharmaceutical has announced the successful completion of a series A financing round, raising over 100 million yuan ($14 million). 21 November 2024
Pharmaceutical
Ascentage Pharma will see its investigational BCL-2 selective inhibitor, lisaftoclax, assessed under China’s Priority Review scheme. 20 November 2024
Pharmaceutical
California, USA-based biotech Cytokinetics saw its shares fall as much as 4% to $9.67 yesterday, after it announced a deal with Germany’ Bayer. 20 November 2024
Biotechnology
Californian oncology-focused biotech Avenzo Therapeutics has announced a pair of important updates. 19 November 2024
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Biosimilars
Following US approval in May this year, South Korea’s Samsung Bioepis and US biotech Biogen have now won approval from the European Commission (EC) for their Opuviz 40mg/mL solution for injection in a vial, a biosimilar referencing Regeneron and Bayer’s Eylea (aflibercept). 18 November 2024
Biotechnology
Shanghai-based Junshi Biosciences has received UK regulatory approval for Loqtorzi (toripalimab) in nasopharyngeal carcinoma (NPC) and esophageal squamous cell carcinoma (ESCC). 18 November 2024
Biotechnology
Chinese biotech Keymed Biosciences has entered an exclusive licensing agreement with Platina Medicines for its bispecific antibody candidate, CM336. 18 November 2024
Pharmaceutical
In yet another sign of the mounting interest in radiopharmaceuticals, Tongrui Biopharma, a Chinese innovator in this area, has announced the completion of a $100 million series A+ financing round. 18 November 2024
Biotechnology
Shanghai-based biopharma Zai Lab has announced the pricing of its underwritten public offering at $25.50 per share, aiming to raise around $200 million. 15 November 2024
Biosimilars
South Korean biosimilars company Celltrion today announced its acquisition of iQone Healthcare Switzerland a specialty pharmaceutical company focused on distribution, sales, and marketing in Switzerland. 15 November 2024
Biotechnology
Merck & Co has entered into an exclusive global license to develop, manufacture and commercialize LM-299 from China-based clinical-stage biotech LaNova Medicines, bringing the US pharma giant into the newly attractive PD-1/VEGF bispecific antibody space. 15 November 2024
Biotechnology
Japanese drugmaker Nippon Shinyaku and USA-based Atsena Therapeutics have entered into an exclusive license agreement for the commercialization of ATSN-101 in the USA and Japan for advancing Atsena’s first- in-class, investigational gene therapy ATSN-101 for Leber congenital amaurosis caused by biallelic mutations in GUCY2D (LCA1). 13 November 2024
Biotechnology
Anglo-American biotech Apollo Therapeutics and China-based Sunshine Lake Pharma have signed an exclusive license agreement to develop APL-18881, a bi-specific fusion protein aimed at treating metabolic diseases. 13 November 2024
Pharmaceutical
Japanese drugmaker Sumitomo Pharma has received approval from China’s National Medical Products Administration (NMPA) for the use of Xenleta (lefamulin acetate) to treat adults with community-acquired pneumonia in injection and tablet formulation. 22 November 2023
Biotechnology
Chinese oncology specialist BeiGene and privately-held Ensem Therapeutics have announced a deal. 21 November 2023
Biotechnology
UK biotech Myricx Bio has announced a licensing agreement with China’s WuXi Biologics. 21 November 2023
Pharmaceutical
Italian family-owned drugmaker Chiesi Farmaceutici has added another investigational product to its list of in-licensed investigational meds, as well as the $1.25 billion acquisition of Anglo-Irish firm Amryt Pharma, this year alone. 20 November 2023
Pharmaceutical
Japanese ophthalmology firm Santen Pharmaceutical has received marketing authorization from the European Commission for Catiolanze (cationic emulsion of latanoprost 50μg/mL, STN1013001). 20 November 2023
Biotechnology
China-based CStone Pharmaceuticals’ Cejemly (sugemalimab) has been approved by the China National Medical Products Administration (NMPA) for the treatment of relapsed or refractory extranodal natural killer/T-cell lymphoma (r/r ENKTL). 20 November 2023
Biotechnology
The European Commission (EC) has granted marketing authorization for China-headquartered biotech BeiGene’s Brukinsa (zanubrutinib) in combination with obinutuzumab for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma. 17 November 2023
Biotechnology
Japanese drugmaker Daiichi Sankyo revealed it has reached an agreement with Japan’s Ministry of Health, Labor and Welfare (MHLW) to supply the omicron XBB.1.5- adapted monovalent mRNA vaccine (DS-5670) against the novel coronavirus infectious disease (COVID19). 17 November 2023
Pharmaceutical
Japanese pharma major Astellas Pharma has entered into a merger agreement to acquire Propella Therapeutics. 16 November 2023
Biotechnology
Antibody specialist Nona Biosciences has entered into a strategic collaboration with Chinese bioconjugation company GeneQuantum Healthcare. 15 November 2023
Pharmaceutical
German drugmaker Boehringer Ingelheim has inked a deal with China’s ChromX Health, aimed at researching ways to improve treatment outcomes for people with interstitial lung diseases. 14 November 2023
Biotechnology
UK pharma major AstraZeneca today announced two developments for its best-selling cancer drug Imfinzi (durvalumab). 14 November 2023
Biotechnology
Japan’s Ajinomoto is moving further into the pharma sector with its proposed acquisition of US biotech firm Forge Biologics. 14 November 2023
Biotechnology
Canadian biotech Zymeworks has reacquired rights for the antibody-drug conjugate (ADC) zanidatamab zovodotin, from partner BeiGene. 13 November 2023
Biotechnology
Following US approval in the same indication earlier this year, Japanese drugmaker Daiichi Sankyo’s Vanflyta (quizartinib) has now also been approved in the European Union (EU). 13 November 2023
Biotechnology
The US Food and Drug Administration yesterday approved Japanese pharma major Takeda’s Adzynma (ADAMTS13, recombinant-krhn; TAK-755), adding to the approval a day earlier of the firm’s bowel cancer drug Fruzaqla (fruquintinib). 10 November 2023
Biotechnology
WuXi XDC has published a prospectus for its upcoming initial public offering (IPO), detailing plans to raise $470 million with a listing on the Hong Kong Stock Exchange. 9 November 2023
Pharmaceutical
China-headquartered Eccogene has entered into an exclusive license agreement with AstraZeneca under which the UK pharma major will develop and commercialize Eccogene's small molecule GLP-1 receptor agonist (GLP-1RA) ECC5004 for the potential treatment of obesity, type-2 diabetes and other comorbidities. 9 November 2023
Pharmaceutical
Japanese drug major Takeda has received US approval for Fruzaqla (fruquintinib), an oral targeted therapy for bowel cancer. 9 November 2023
Biotechnology
East Coast, USA-based biotech incubator Flagship Pioneering is expanding into the Asia-Pacific, with a new regional hub in Singapore. 8 November 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze